Skip to main content

Table 3 Analysis of time to first CID by selected eosinophil cut-offs (pooled analysis; full study duration)

From: Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

Cut-off, ×109/L (% ≤)

Lower stratum

Upper stratum

BUD/FORM 160/4.5 μg bid

FORM

4.5 μg bid

HR (95% CI)

BUD/FORM 160/4.5 μg bid

FORM

4.5 μg bid

HR (95% CI)

0.10 (25.2)

201/285 (70.5)

199/291 (68.4)

0.97 (0.80–1.18)

569/857 (66.4)

633/853 (74.2)

0.67 (0.60–0.75)

0.15 (44.8)

350/503 (69.6)

373/520 (71.7)

0.82 (0.71–0.95)

420/639 (65.7)

459/624 (73.6)

0.68 (0.59–0.77)

0.20 (60.9)

466/675 (69.0)

519/718 (72.3)

0.78 (0.69–0.88)

304/467 (65.1)

313/426 (73.5)

0.69 (0.59–0.80)

0.25 (73.1)

560/818 (68.5)

613/852 (71.9)

0.78 (0.69–0.87)

210/324 (64.8)

219/292 (75.0)

0.64 (0.53–0.78)

0.30 (79.9)

616/896 (68.8)

670/931 (72.0)

0.79 (0.71–0.88)

154/246 (62.6)

162/213 (76.1)

0.57 (0.46–0.71)

0.35 (85.2)

659/965 (68.3)

708/983 (72.0)

0.77 (0.69–0.86)

111/177 (62.7)

124/161 (77.0)

0.58 (0.45–0.75)

  1. Numbers shown: event/total (%)
  2. bid, twice daily; BUD Budesonide, CID Clinically Important Deterioration, CI Confidence interval, FORM Formoterol, HR Hazard ratio